GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Aeterna Zentaris, Inc. (AEZS) [hlAlert]

Rating:
Buy AEZS
down 97.50 %

Aeterna Zentaris, Inc. (AEZS) rated Buy by Janney Mntgmy Scott

Posted on: Thursday,  Nov 6, 2008  9:25 AM ET by Janney Mntgmy Scott

Janney Mntgmy Scott rated Buy Aeterna Zentaris, Inc. (NASDAQ: AEZS) on 11/06/2008, when the stock price was $3.60.
Since then, Aeterna Zentaris, Inc. has lost 97.50% as of 12/02/2015's recent price of $0.09.
If you would have followed this Janney Mntgmy Scott's recommendation on AEZS, you would have lost 97.5% of your investment in 2582 days.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology. The product pipeline of the Company encompasses compounds at all stages of development, from drug discovery through marketed products. The Company’s principal product candidates include cetrorelix for benign prostatic hyperplasia (BPH) and AEZS-108 for endometrial and ovarian cancers. In January 2007, the Company completed the spin-off of Atrium Biotechnologies Inc., known as Atrium Innovations (Atrium). On November 30, 2007, the Company completed the sale of its Utah-based subsidiary, Echelon Biosciences Inc. (Echelon), to Frontier Scientific Inc.

We are committed to providing innovative, wealth-building investment solutions through original thought, proprietary data and access to company managements, industry leaders and our analysts. Janney’s enduring commitment to primary research coincides with an investment acumen that recognizes our core responsibility – to make money for our clients. Our analysts strive to identify the emerging and sometimes hidden themes that can provide investors a superior return over time.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/6/2008 9:25 AM Buy
None
3.60
as of 12/24/2008
1 Week down  -10.93 %
1 Month up  35.71 %
3 Months up  132.65 %
1 YTD up  132.65 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy